Erin Wright, an analyst from Morgan Stanley, maintained the Buy rating on BrightSpring Health Services, Inc.. The associated price target remains the same with $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Erin Wright has given his Buy rating due to a combination of factors including BrightSpring Health Services’ strong performance in its Pharmacy Solutions segment, which has shown impressive growth. The company’s second-quarter EBITDA exceeded expectations, and its revenue growth was significantly higher than anticipated, driven by a notable increase in Pharmacy Solutions sales. This segment, particularly in areas like Specialty and Infusion, has consistently demonstrated robust growth, contributing positively to the company’s financial outlook.
Additionally, BrightSpring Health Services has raised its guidance for 2025, projecting continued revenue growth across its segments. The divestiture of its Community Living business is expected to streamline operations and reduce Medicaid exposure, which is seen as a positive strategic move. These factors, combined with a clean operational performance and the potential for further growth in the healthcare services sector, underpin Wright’s optimistic outlook and Buy rating for the stock.
In another report released on July 23, BTIG also maintained a Buy rating on the stock with a $30.00 price target.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BTSG in relation to earlier this year.